Animal model of autism

The development of an animal model of autism is one approach researchers use to study potential causes of autism.^[1] Given the complexity of autism and its etiology, researchers often focus only on single features of autism when using animal models.^[2]

Rodent model

One of the more common rodent models is the Norway rat (Rattus norvegicus).^[3] More recent research has used the house mouse (Mus musculus) to model autism because it is a social species. Other strains of mice used include mu opioid receptor knockout mice, as well as Fmr1 knockout mice; the latter are also used as animal models of Fragile X syndrome.^[4]

The Norway rat has been used, for example, by Mady Hornig to implicate thiomersal in autism.^[5][6] The current scientific consensus is that no convincing scientific evidence supports these claims,^[7][8] and major scientific and medical bodies such as the Institute of Medicine^[7] and World Health Organization^[9] (WHO) as well as governmental agencies such as the U.S. Food and Drug Administration^[10] (FDA) and Centers for Disease Control and Prevention^[11] (CDC) reject any role for thiomersal in autism or other neurodevelopmental disorders.

Behaviors measured in these models include approach to olfactory pheromones emitted by other mice, approach to familiar and new conspecifics, reciprocal social interactions, ultrasonic vocalizations, communal nesting, sexual and parenting behaviors, territorial scent marking, and aggressive behaviors, as well as motor behaviors such as gait.^[12][13] Social interaction is measured by how the mouse interacts with a stranger mouse introduced in the opposite side of a test box.^[14]

Researchers from the University of Florida have used deer mice to study restricted and repetitive behavior such as compulsive grooming, and how these behaviors may be caused by specific gene mutations.^[15] In addition, Craig Powell of the University of Texas Southwestern Medical Center, with a grant from Autism Speaks,^[16] is currently using mice to examine the potential role of neuroligin gene mutations in causing autism. Much research has been done into the use of a rat model to show how Borna virus infection,^[17][18] exposure to valproic acid in utero,^[19] and maternal immune activation^[20] may cause autism.

Another goal of the use of rodent models to study autism is to identify the mechanism by which autism develops in humans.^[1] Other researchers have developed an autism severity score to measure the degree of severity of the mice's autism, as well as the use of scent marking behavior^[21] and vocalization distress^[14] as models for communication.

It has been observed that mice lacking the gene for oxytocin exhibit deficits in social interaction, and that it may be possible to develop treatments for autism based on abnormalities in this and other neuropeptides.^[22][23] A mutation in the Cntnap2 gene, which has been linked to ASD in human, results in decreased oxytocin levels in mice. Supplementing affected mice with oxytocin has been found to improve these social deficits, indicating potential therapeutic insights for improving social behaviors in this model. However, recent studies have emphasized that the majority of risk factors identified for autism do not directly connect to the oxytocin signaling pathway. This highlights that while oxytocin's role is significant, ASD is complex with a wide array of genetic influences, many of which may affect different biological pathways not directly related to oxytocin. ^[24]

Environmental Factors of ASD

Looking at the environmental factors of autistic spectrum disorder in rodents helps us to understand the neuropathology of the disorder which can be compared to humans. Environmental factors have been studied in animal rodent models and have been seen to influence brain development and play a role in gene expression. Recent advancements in research on ASD in rodent models illustrate that the interaction between genetic predispositions and environmental exposures. These exposures, which span from prenatal factors such as maternal infections and diet to postnatal experiences including exposure to toxicants, insecticides, and certain medications, are increasingly recognized for their critical roles in the neuropathology of ASD. ^[25] [26]Specifically, a detailed analysis recognizes how these factors may heighten the susceptibility to developing ASD disrupting the neurodevelopmental process. Studies have observed an increase in immune cells of the prefrontal cortex and an augmentation of support cells in the hippocampus due to toxins in rodent models, particularly those treated with valproic acid (VPA). ^[25]This link between environmental exposures and distinct neurobiological alterations remains unpredictable largely due to the variability of timing. Since environmental factors can occur at any time during the developmental process, there is much variability in the neural and behavioral phenotype of autism. The environment can cause unknown changes in brain development of rodents because they don't all live in the same habitat and therefore might develop different changes to their brain than what is expected.

Maternal immune activation has also been associated with increased risk for development of neurodevelopmental disorders.^[27] Maternal immune activation is when inflammatory pathways are activated during pregnancy, usually by an infection. These inflammatory pathways involve the release of cytokines, or immune signaling proteins. Recent studies have shown that changes in the expression of cytokines during early stages of life are linked to the likelihood of experiencing neurodevelopmental disorders such as autism spectrum disorder (ASD) and significant developmental delay.^[2] Injection of Poly(I:C), which is an immunostimulant and mimics viral infection, to pregnant rodents has been shown to induce an inflammatory response in the brain of the offspring, induce structural brain changes in the offspring, and bring about behavioral changes such as hyperactivity, more aggressive behavior, and less social behavior in the offspring.^[28] In addition to viral infection, lipopolysaccharides (LPS) has been used to mimic bacterial infection in rodents in order to observe the effects on the offspring. LPS had similar effects as Poly(I:C) on the immune system of the offspring, increasing inflammation.^[29] This inflammatory state in the offspring lasted until adulthood, indicating the long-lasting effects of maternal immune activation.^[29] Overall, recent studies make a case for infection during pregnancy being an environmental risk factor for neurodevelopmental disorders such as ASD or schizophrenia in rodents.

Genetic and Phenotypic Factors of ASD

There have been six autism-related genes that are linked to the X chromosome when it comes to autistic spectrum disorder.⁵ The first gene that has been linked to autism is the Fragile X mental retardation gene (Fmr1). For example, rodents with this gene exhibit elevated cortical spine densities that are similar to those found in autism as well as decreased social behaviors. Another gene that has been linked to autism is methyl-CpG- binding protein type 2 gene (MECP2). In the rodent models that have MECP2 disruption, the rodents are usually normal up until the sixteenth week of age and then they start to develop extreme anxiety in the field, reduced nest building, and poor social interactions which are all symptoms of autism¹. The third and fourth genes that have been linked to autism are neuroligin (NLGN) 3 and 4 genes. One study found that mutations in the NLGN 3 and 4 genes lead to loss of neuroligin processing to stimulate the formation of synapses which is a feature of autistic spectrum disorders². The fifth and sixth genes that are linked to autism are the tuberous sclerosis genes (TSC1 and TSC2). Mutations in one of these two genes cause multiple benign tumors to grow in multiple tissues like the brain². Lastly, many of the abnormalities found in autistic spectrum disorders involve the mTOR signaling pathway, the GABA - containing neurons, and the immune system.

Human Autism Spectrum Disorder

Understanding human neurodevelopmental disorders often requires adequate models to understand the overall nature of the disorder and the general impacts the disorder makes on the brain itself. Naturally each disorder has different implications when it comes to genetic makeup, phenotypically and genotypically, and generally this impacts particular brain regions. In Autism Spectrum Disorder (ASD) it is generally seen in reduced developmental growth within the brain, and more specifically reduced gray matter within the medial temporal lobe (MTL), which is where the amygdala and hippocampus are located. This is critical in understanding Autism because this region of the brain controls emotions and learning, which is symptomatically linked to ASD. In addition, this supports the need for animal models that establish a greater understanding of what effects these particular brain regions and genetics have on development, and if there are measures we can take to prevent the onset of the disorder³.

Neuropathology of the Underdeveloped Synapse

Autism Spectrum Disorder (ASD) is caused by developmental delays that cause the brain to have lower connectivity within particularly important regions. The synapses within the brain have critical importance in development in young children, especially during their critical period. Autistic brains often have delayed or early critical periods, causing complications within the brain's developmental stages and ability to create stronger synapses for basic communication and stimulus recognition⁴. Furthermore, the brain's lessened development and cognitive delays are usually observable within the genetics and grey matter within the brain³.

Rodent models have been established as good examples because their brains are akin to humans in makeup. Additionally, they have similar social interactions and relationships that humans have, which shows the social development symptoms often used to diagnose ASD. Rodents when used as models are compared to their normal developed brains, but to replicate ASD, the rodents are lesioned prior to birth using prenatal valproate (VPA). The rodents then experience similar symptoms and developmental changes that occur with human's with ASD. Human's with ASD are identified to have a single-gene mutation at Neuroligin-3, or NL-3 R451C. These particularly simple changes to the rodents and human brains impact them greatly in their ability to develop properly⁴.

Neuropathology of GABA Receptors

Rodents, most especially mice, are excellent animal models of autism because they have similar social relationships and neuroscience. When exposed to prenatal valproate (VPA) during pregnancy, the mice are born with basic deformities and the developmental delays seen symptomatically in humans⁵. This is all comparable and easier to study since the lifespan of mice and most rodents is shorter, so being able to understand the genetics, minute effects, and test methods to reduce the onset of the disorder allows for researchers to develop new treatment methods quickly and effectively to help humans on the spectrum. Additionally, these rodents may trace back particular models to how the developmental delays occur in relation to GABA5. GABA is a neurotransmitter that is generally seen as inhibitory, but prior to birth and in early development of the brain it is often excitatory while neurons establish proper brain chemistry. During development there are specific times, called critical periods, where the brain is more capable of acquiring neural connections which usually leads to new behavioral and psychological skills. GABA's change from excitatory to inhibitory, as well as other neurotransmitter changes during these critical developmental stages can impact the development the brain goes through. If the critical period is early, growth can be limited, slowed, or even stunted early on. Additionally, if it is later, the brain's development is measured as complete incorrectly which may limit its ability to improve connectivity. Overall, the brain's circuitry and communication is often limited or poor within ASD, so using rodent models to study these limitations and where they come about increases researchers' understanding of the disorder and potential ways to prevent it⁵.

Songbird model

In 2012, a researcher from the University of Nebraska at Kearney published a study reviewing research that had been done using the zebra finch as a model for autism spectrum disorders, noting that the neurobiology of vocalization is similar between humans and songbirds, and that, in both species, social learning plays a central role in the development of the ability to vocalize.^[30] These parallels extend to the FOXP2 gene, expressed significantly in various parts of CNS, including areas crucial for motor functions, from embryonic development through adulthood.^[31] Other research using this model has been done by Stephanie White at the University of California Los Angeles, who studied mutations in the FOXP2 gene and its potential role in learned vocalization in both songbirds (specifically the zebra finch) and humans.^[32][33] Further research has elucidated how FOXP2 and its associated gene FOXP1 are distributed in language- related brain centers, influencing vocal learning through mechanisms that affect the formation of vocalization- related memories and the neural substrates of song and speech.^[34] In zebra finches, knockdown of FOXP2 in the basal ganglia song nucleus Area X impairs singing, supporting the gene's role in the regulation of song production. Younger birds with knocked down FOXP1 expression have displayed selective learning deficits, impacting their ability to form memories essential for the cultural transmission of behavior, such as learning adult model songs.^[34]

Controversy

In 2013, a study was published by Swiss researchers which concluded that 91% (31 out of the 34 studies reviewed) of valproic acid-autism studies using animal models had statistical flaws—specifically, they had failed to correctly use the litter as a level of statistical analysis rather than just the individual (i.e., an individual mouse or rat).^[35][36]

References

1. Bourgeron T, Jamain SP, Granon S (2006). "Animal Models of Autism: Proposed Behavioral Paradigms and Biological Studies". Transgenic and Knockout Models of Neuropsychiatric Disorders. Contemporary Clinical Neuroscience. pp. 151–174. doi:10.1007/978-1-59745-058-4_8. ISBN 978-1-58829-507-1.
2. Bilbo SD, Block CL, Bolton JL, Hanamsagar R, Tran PK (2018-01-01). "Beyond infection - Maternal immune activation by environmental factors, microglial development, and relevance for autism spectrum disorders". Experimental Neurology. 299 (Pt A): 241–251. doi:10.1016/j.expneurol.2017.07.002. ISSN 0014-4886. PMC 5723548. PMID 28698032.
3. Callaway E (2011). "Rat models on the rise in autism research". Nature. doi:10.1038/nature.2011.9415. S2CID 143857251.
4. Oddi D, Crusio WE, d'Amato FR, Pietropaolo S (2013). "Monogenic mouse models of social dysfunction: Implications for autism". Behavioural Brain Research. 251: 75–84. doi:10.1016/j.bbr.2013.01.002. PMID 23327738. S2CID 10384899.
5. "Vaccine Links To Autism?". www.cbsnews.com. 22 June 2004.
6. Hornig M, Chian D, Lipkin WI (2004). "Neurotoxic effects of postnatal thimerosal are mouse strain dependent". Molecular Psychiatry. 9 (9): 833–845. doi:10.1038/sj.mp.4001529. PMID 15184908.
7. Institute of Medicine (2004). Immunization Safety Review: Vaccines and Autism. Washington, DC: The National Academies Press. doi:10.17226/10997. ISBN 978-0-309-09237-1. PMID 20669467.
8. Doja A, Roberts W (2006). "Immunizations and autism: a review of the literature". Can J Neurol Sci. 33 (4): 341–6. doi:10.1017/s031716710000528x. PMID 17168158.
9. World Health Organization (2006). . Archived from the original on October 12, 2003. Retrieved 2009-05-19.
10. "Thimerosal in vaccines". Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. 2008-06-03. Retrieved 2008-07-25.
11. Centers for Disease Control (2008-02-08). "Mercury and vaccines (thimerosal)". Retrieved 2011-08-01.
12. Crawley JN (2012). "Translational animal models of autism and neurodevelopmental disorders". Dialogues in Clinical Neuroscience. 14 (3): 293–305. doi:10.31887/DCNS.2012.14.3/jcrawley. PMC 3513683. PMID 23226954.
13. Robertson H. "How is a Mouse Like a Person?". The University of Chicago Neuroscience Institute. Retrieved 14 August 2021.
14. Klauck SM, Poustka A (2006). "Animal models of autism". Drug Discovery Today: Disease Models. 3 (4): 313–318. doi:10.1016/j.ddmod.2006.11.005.
15. Lewis M, Tanimura Y, Lee L, Bodfish J (2007). "Animal models of restricted repetitive behavior in autism". Behavioural Brain Research. 176 (1): 66–74. doi:10.1016/j.bbr.2006.08.023. PMC 3709864. PMID 16997392.
16. "Science Blog | Autism Speaks". www.autismspeaks.org.
17. Libbey J, Sweeten T, McMahon W, Fujinami R (2005). "Autistic disorder and viral infections". Journal of NeuroVirology. 11 (1): 1–10. doi:10.1080/13550280590900553. PMID 15804954. S2CID 9962647.
18. Pletnikov MV, Moran TH, Carbone KM (2002). "Borna disease virus infection of the neonatal rat: Developmental brain injury model of autism spectrum disorders". Frontiers in Bioscience. 7 (1–3): d593–d607. doi:10.2741/pletnik. PMID 11861216.
19. Roullet FI, Lai JK, Foster JA (2013). "In utero exposure to valproic acid and autism — A current review of clinical and animal studies". Neurotoxicology and Teratology. 36: 47–56. doi:10.1016/j.ntt.2013.01.004. PMID 23395807.
20. Parker-Athill EC, Tan J (2010). "Maternal Immune Activation and Autism Spectrum Disorder: Interleukin-6 Signaling as a Key Mechanistic Pathway". Neurosignals. 18 (2): 113–128. doi:10.1159/000319828. PMC 3068755. PMID 20924155.
21. Wöhr M, Scattoni ML (2013). "Behavioural methods used in rodent models of autism spectrum disorders: Current standards and new developments". Behavioural Brain Research. 251: 5–17. doi:10.1016/j.bbr.2013.05.047. PMID 23769995. S2CID 44281498.
22. Lim MM, Bielsky IF, Young LJ (2005). "Neuropeptides and the social brain: Potential rodent models of autism". International Journal of Developmental Neuroscience. 23 (2–3): 235–243. CiteSeerX 10.1.1.326.275. doi:10.1016/j.ijdevneu.2004.05.006. PMID 15749248. S2CID 17820205.
23. Chadman KK, Guariglia SR, Yoo JH (2012). "New directions in the treatment of autism spectrum disorders from animal model research". Expert Opinion on Drug Discovery. 7 (5): 407–416. doi:10.1517/17460441.2012.678828. PMID 22494457. S2CID 25385007.
24. Hörnberg H, Pérez-Garci E, Schreiner D, Hatstatt-Burklé L, Magara F, Baudouin S, Matter A, Nacro K, Pecho-Vrieseling E, Scheiffele P (August 2020). "Rescue of oxytocin response and social behaviour in a mouse model of autism". Nature. 584 (7820): 252–256. Bibcode:2020Natur.584..252H. doi:10.1038/s41586-020-2563-7. ISSN 1476-4687. PMC 7116741. PMID 32760004.
25. Wang L, Wang B, Wu C, Wang J, Sun M (January 2023). "Autism Spectrum Disorder: Neurodevelopmental Risk Factors, Biological Mechanism, and Precision Therapy". International Journal of Molecular Sciences. 24 (3): 1819. doi:10.3390/ijms24031819. ISSN 1422-0067. PMC 9915249. PMID 36768153.
26. Pensado-López A, Veiga-Rúa S, Carracedo Á, Allegue C, Sánchez L (November 2020). "Experimental Models to Study Autism Spectrum Disorders: hiPSCs, Rodents and Zebrafish". Genes. 11 (11): 1376. doi:10.3390/genes11111376. ISSN 2073-4425. PMC 7699923. PMID 33233737.
27. Haddad FL, Patel SV, Schmid S (June 2020). "Maternal Immune Activation by Poly I:C as a preclinical Model for Neurodevelopmental Disorders: A focus on Autism and Schizophrenia". Neuroscience and Biobehavioral Reviews. 113: 546–567. doi:10.1016/j.neubiorev.2020.04.012. ISSN 1873-7528. PMID 32320814. S2CID 215823322.
28. Goh JY, O'Sullivan SE, Shortall SE, Zordan N, Piccinini AM, Potter HG, Fone KC, King MV (2020-10-01). "Gestational poly(I:C) attenuates, not exacerbates, the behavioral, cytokine and mTOR changes caused by isolation rearing in a rat 'dual-hit' model for neurodevelopmental disorders". Brain, Behavior, and Immunity. 89: 100–117. doi:10.1016/j.bbi.2020.05.076. ISSN 0889-1591. PMID 32485291. S2CID 219123682.
29. Talukdar PM, Abdul F, Maes M, Binu VS, Venkatasubramanian G, Kutty BM, Debnath M (October 2020). "Maternal Immune Activation Causes Schizophrenia-like Behaviors in the Offspring through Activation of Immune-Inflammatory, Oxidative and Apoptotic Pathways, and Lowered Antioxidant Defenses and Neuroprotection". Molecular Neurobiology. 57 (10): 4345–4361. doi:10.1007/s12035-020-02028-8. ISSN 1559-1182. PMID 32720073. S2CID 220775269.
30. Panaitof SC (2012). "A songbird animal model for dissecting the genetic bases of autism spectrum disorder". Disease Markers. 33 (5): 241–249. doi:10.1155/2012/727058. PMC 3810686. PMID 22960335.
31. Lüffe TM, D'Orazio A, Bauer M, Gioga Z, Schoeffler V, Lesch KP, Romanos M, Drepper C, Lillesaar C (2021-10-14). "Increased locomotor activity via regulation of GABAergic signalling in foxp2 mutant zebrafish—implications for neurodevelopmental disorders". Translational Psychiatry. 11 (1): 1–12. doi:10.1038/s41398-021-01651-w. ISSN 2158-3188. PMC 8517032. PMID 34650032.
32. . Archived from the original on 2016-12-19. Retrieved 2013-12-10.
33. Condro MC, White SA (2014). "Distribution of language-related Cntnap2 protein in neural circuits critical for vocal learning". Journal of Comparative Neurology. 522 (1): 169–185. doi:10.1002/cne.23394. PMC 3883908. PMID 23818387.
34. Csillag A, Ádám Á, Zachar G (2022). "Avian models for brain mechanisms underlying altered social behavior in autism". Frontiers in Physiology. 13. doi:10.3389/fphys.2022.1032046. ISSN 1664-042X. PMC 9650632. PMID 36388132.
35. Lazic SE, Essioux L (2013). "Improving basic and translational science by accounting for litter-to-litter variation in animal models". BMC Neuroscience. 14: 37. doi:10.1186/1471-2202-14-37. PMC 3661356. PMID 23522086.
36. Varughese, Ansa (2 April 2013). "New Study Says 91% Of Autism Studies Using Certain Animal Models Are Statistically Flawed". Medical Daily. Retrieved 10 December 2013.

Other sources

• Gadded B (2013). "Neuropathology and Animal Models of Autism: Genetic and Environmental Factors". Autism Research and Treatment. 2013: 1–12. doi:10.1155/2013/731935. PMC 3787615. PMID 24151553.